Figure 5. Circuit deficits from VIP-Cre.Scn1a^fl/+ mice closely resemble the global model following pharmacologically enhanced muscarinic activation.

(A) Diagram of experimental design for (B) to (H). After a single FOV was recorded as above, the mouse was injected with low subconvulsive 10 mg/kg pilocarpine, and the same FOV was recorded 10 min later.

(B and C) Heatmap showing activity for each cell at the onset of locomotion bouts, as in Figures 4D and 4E, following the application of pilocarpine.

(D) Averaged dF/F₀ response, as in (C), aligned to locomotion bouts, after the injection pilocarpine.

(E) Example of the dF/F₀ trace from a single VIP and non-VIP neuron aligned to a single locomotion bout onset, with the same cells shown below after intraperitoneal injection of pilocarpine.

(F) Same as (E) but for example cells from a VIP-Cre.Scn1a^+/fl mouse.

(G) The effect of pilocarpine on deconvolved event frequencies during stationary epochs calculated as an index value.

(H) The effect of pilocarpine on deconvolved event frequencies during locomotion epochs calculated as an index value.

(I) Locomotion MI for VIP and non-VIP cells after injection of pilocarpine.

(J) Fraction of cells either activated (+) or inhibited (−) during locomotion after the injection of pilocarpine, compared across genotypes as above.

For (B) to (H) and (I), n = 2,068 tdT⁻ and 119 VIP-INs from N = 6 WT (4 male, 2 female) mice; n = 2,384 tdT⁻ and 178 VIP-INs from N = 7 Scn1a^+/fl mice (3 male, 4 female).